/DICE

DICE Stock - DICE Therapeutics, Inc.

Q: What is the analyst price target for DICE?

Analyst price target information is not currently available for DICE.

Q: What is DICE's market cap?

Market capitalization information is not currently available for DICE.

Healthcare|Biotechnology|NASDAQ

$47.55+0.06%

+$0.03 (+0.06%) • Aug 8

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+5.2%upside

Target: $50.02

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DICE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$47.90

52W Low$15.08

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019
Revenue	N/A	$1.13M	$863,000	$5.78M
Gross Profit	N/A	$1.13M	$863,000	$5.78M
Gross Margin	N/A	100.0%	100.0%	100.0%
Operating Income	$-88,221,000	$-47,603,000	$-23,721,000	$-13,547,000
Net Income	$-81,664,000	$-48,472,000	$-23,752,000	$-12,964,000
Net Margin	N/A	-4308.6%	-2752.3%	-224.5%
EPS	$-2.07	$-3.91	$-1.02	$-0.56

Company Overview

DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE, is designed to discover selective oral small molecules to modulate protein-protein interactions (PPIs) as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17, which is a validated drug target implicated in a various immunology indications. It is also developing oral therapeutic candidates targeting a4ß7 integrin for the treatment of inflammatory bowel diseases, as well as targeting aVß1/aVß6 integrin for the treatment of idiopathic pulmonary fibrosis. In addition, the company focuses on immuno-oncology for antibody therapeutics. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

86%

Hold / Neutral

14%

Sell / Underperform

Analyst Consensus🟢 Bullish

6 Bullish1 Neutral/Bearish

Price Targets

$49

Average Target

↑ 3.0% Upside

Now

$36

Low

$49

Average

$71

High

Based on 7 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 24th 2023	Wells Fargo	Initiation	Equal Weight	$38
May 22nd 2023	Canaccord Genuity	Initiation	Buy	$71
March 31st 2023	Needham	Initiation	Buy	$56
March 1st 2023	Cowen	Initiation	Outperform	-
November 15th 2022	Guggenheim	Initiation	Buy	$65
September 14th 2022	Cantor Fitzgerald	Initiation	Overweight	$36
September 7th 2022	Stifel	Initiation	Buy	$37
July 18th 2022	H.C. Wainwright	Initiation	Buy	$40

Earnings History & Surprises

DICE

Beat Rate

63%

Last 8 quarters

Avg Surprise

+48.5%

EPS vs Estimate

Beats / Misses

5/3

Last 12 quarters

Latest EPS

$-0.74

Q3 2023

EPS Surprise History

Q4 21

+360.0%

$2.30vs$0.50

Q1 22

+24.1%

$-0.44vs$-0.58

Q2 22

+7.4%

$-0.50vs$-0.54

Q3 22

-3.6%

$-0.58vs$-0.56

Q4 22

+9.8%

$-0.55vs$-0.61

Q1 23

-4.1%

$-0.51vs$-0.49

Q2 23

+8.5%

$-0.54vs$-0.59

Q3 23

-13.8%

$-0.74vs$-0.65

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 10, 2024	—	—	—	—
Q1 2024	Mar 14, 2024	—	—	—	—
Q4 2023	Nov 8, 2023	$-0.69	—	—	—
Q3 2023	Aug 8, 2023	$-0.65	$-0.74	-13.8%	✗ MISS
Q2 2023	May 11, 2023	$-0.59	$-0.54	+8.5%	✓ BEAT
Q1 2023	Mar 15, 2023	$-0.49	$-0.51	-4.1%	✗ MISS
Q4 2022	Nov 9, 2022	$-0.61	$-0.55	+9.8%	✓ BEAT
Q3 2022	Aug 11, 2022	$-0.56	$-0.58	-3.6%	✗ MISS
Q2 2022	May 12, 2022	$-0.54	$-0.50	+7.4%	✓ BEAT
Q1 2022	Mar 21, 2022	$-0.58	$-0.44	+24.1%	✓ BEAT
Q4 2021	Nov 12, 2021	$0.50	$2.30	+360.0%	✓ BEAT
Q3 2021	Sep 16, 2021	—	$-0.21	—	—
Q1 2021	Mar 31, 2021	—	$-0.35	—	—
Q4 2020	Dec 31, 2020	—	$-0.26	—	—
Q3 2020	Sep 30, 2020	—	$-0.26	—	—

Frequently Asked Questions about DICE

What is DICE's current stock price?

DICE Therapeutics, Inc. (DICE) is currently trading at $47.55 per share. The stock has moved +0.06% today.

What is the analyst price target for DICE?

The average analyst price target for DICE is $50.00, based on 1 analyst.

What sector is DICE Therapeutics, Inc. in?

DICE Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is DICE's market cap?

DICE Therapeutics, Inc. has a market capitalization of $2.27 billion, making it a mid-cap company.

Does DICE pay dividends?

No, DICE Therapeutics, Inc. does not currently pay a dividend to shareholders.